We are live on ! Find out more
PAWC

P.A.W. Capital Portfolio holdings

AUM $131M
1-Year Est. Return 46.14%
This Fund
S&P 500
This Quarter Est. Return
+55.79%
1 Year Est. Return
+46.14%
3 Year Est. Return
+67.18%
5 Year Est. Return
+64.85%
10 Year Est. Return
+1,459.33%
AUM
$93.8M
AUM Growth
+$13.6M
Cap. Flow
-$4.61M
Cap. Flow %
-4.92%
Top 10 Hldgs %
41.34%
Holding
68
New
7
Increased
10
Reduced
25
Closed
7

Top Buys

Rank Stock Value
1
OPRX icon
OptimizeRx
OPRX
+$2.78M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$851K
3
SYRE icon
Spyre Therapeutics
SYRE
+$785K
4
SIX
Six Flags Entertainment Corp.
SIX
+$736K
5
WFC icon
Wells Fargo
WFC
+$629K

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$1.44M
2
MNDT
Mandiant, Inc. Common Stock
MNDT
+$1.2M
3
RGNX icon
Regenxbio
RGNX
+$1.19M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$1.12M
5
EVER icon
EverQuote
EVER
+$780K

Sector Composition

Rank Sector Weight
1 Technology 28.13%
2 Healthcare 25.68%
3 Communication Services 15.38%
4 Consumer Staples 9.73%
5 Financials 5.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSFT icon
26
Microsoft
MSFT
$2.92T
$946K 1.01%
6,000
+1,000
+20% +$147K
JPM icon
27
JPMorgan Chase
JPM
$950B
$767K 0.82%
5,500
-500
-8% -$64.1K
SYRE icon
28
Spyre Therapeutics
SYRE
$8.68B
$764K 0.81%
+4,000
New +$785K
CCL icon
29
Carnival Corporation Ltd
CCL
$38.7B
$762K 0.81%
15,000
– –
BP icon
30
BP
BP
$107B
$755K 0.81%
20,000
+4,000
+25% +$152K
RDS.A
31
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$737K 0.79%
12,500
+500
+4% +$29.2K
JNJ icon
32
Johnson & Johnson
JNJ
$643B
$729K 0.78%
5,000
– –
MRK icon
33
Merck
MRK
$326B
$728K 0.78%
8,384
– –
SIX
34
DELISTED
Six Flags Entertainment Corp.
SIX
$722K 0.77%
+16,000
New +$736K
DOW icon
35
Dow Inc
DOW
$20.8B
$711K 0.76%
13,000
-2,000
-13% -$103K
ABBV icon
36
AbbVie
ABBV
$465B
$708K 0.75%
8,000
– –
MMM icon
37
3M
MMM
$94.1B
$706K 0.75%
4,784
+2,392
+100% +$335K
GSK icon
38
GSK
GSK
$108B
$705K 0.75%
12,000
-800
-6% -$44.5K
SLB icon
39
SLB Ltd
SLB
$74.2B
$704K 0.75%
+17,500
New +$625K
T icon
40
AT&T
T
$169B
$703K 0.75%
23,832
-2,648
-10% -$76.5K
MO icon
41
Altria Group
MO
$125B
$699K 0.75%
14,000
-1,000
-7% -$47.2K
ABT icon
42
Abbott
ABT
$187B
$695K 0.74%
8,000
– –
PFE icon
43
Pfizer
PFE
$144B
$686K 0.73%
18,445
– –
PEP icon
44
PepsiCo
PEP
$195B
$683K 0.73%
5,000
– –
PM icon
45
Philip Morris
PM
$312B
$681K 0.73%
8,000
– –
VZ icon
46
Verizon
VZ
$201B
$675K 0.72%
11,000
-1,000
-8% -$60.3K
ARCC icon
47
Ares Capital
ARCC
$13.7B
$671K 0.72%
36,000
-4,000
-10% -$74.3K
CVX icon
48
Chevron
CVX
$374B
$663K 0.71%
5,500
– –
WFC icon
49
Wells Fargo
WFC
$263B
$646K 0.69%
+12,000
New +$629K
KHC icon
50
Kraft Heinz
KHC
$32.4B
$643K 0.69%
20,000
– –
1
2
3

Similar funds

EIM
Emmett Investment Management New York $131M AUM 25.7% 1-Year Est. Return
CIP
Castlefield Investment Partners Manchester $131M AUM
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
LC
LTG Capital Newton, Massachusetts $131M AUM 19.7% 1-Year Est. Return
EWP
Evergreen Wealth Partners Kalispell, Montana $131M AUM
OIM
Oder Investment Management Woodland Hills, California $130M AUM 25.54% 1-Year Est. Return
EPI
Eddie Patel Inc Chicago, Illinois $130M AUM

P.A.W. Capital's Q4 2019 Portfolio in Review

As of Q4 2019, P.A.W. Capital held 68 positions worth $93.8M, up 17% from $80.2M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

P.A.W. Capital withdrew a net $4.61M in Q4 2019, closing 7 positions and reducing 25 holdings. Its most notable exit was Mandiant, Inc. Common Stock, an estimated $1.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 34% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, P.A.W. Capital opened a new position in Orchard Therapeutics plc American Depositary Shares worth $963K.

  • P.A.W. Capital's largest Q4 2019 buy was Orchard Therapeutics plc American Depositary Shares: 7,000 shares worth $963K.
  • P.A.W. Capital added most to OptimizeRx in Q4 2019, an estimated $2.78M increase.
  • P.A.W. Capital's biggest Q4 2019 reduction was Constellation Pharmaceuticals, Inc., cutting an estimated $1.44M.
  • P.A.W. Capital fully exited Mandiant, Inc. Common Stock in Q4 2019, selling an estimated $1.2M.
  • P.A.W. Capital's ten largest holdings make up 41% of its $93.8M portfolio in Q4 2019.
  • P.A.W. Capital opened 7 new positions and closed 7 in Q4 2019.
  • P.A.W. Capital's portfolio value rose 17% quarter-over-quarter to $93.8M.

Based on P.A.W. Capital's 13F filing for Q4 2019, filed 28 Jan 2020.